DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Consensus Target Price from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.3333.

DMAC has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital restated a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. TD Cowen initiated coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of DiaMedica Therapeutics in a report on Friday, November 14th. They set an “overweight” rating on the stock. Finally, Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC opened at $8.14 on Friday. The company has a 50 day simple moving average of $8.36 and a two-hundred day simple moving average of $7.11. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $10.42. The company has a market capitalization of $423.93 million, a price-to-earnings ratio of -11.46 and a beta of 1.11.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Activity at DiaMedica Therapeutics

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg purchased 73,099 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was purchased at an average price of $8.57 per share, for a total transaction of $626,458.43. Following the completion of the purchase, the insider directly owned 8,825,742 shares of the company’s stock, valued at $75,636,608.94. This trade represents a 0.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 1,061,277 shares of company stock valued at $7,632,627. 7.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DiaMedica Therapeutics

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in DiaMedica Therapeutics during the 3rd quarter valued at about $27,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at approximately $29,000. Police & Firemen s Retirement System of New Jersey bought a new position in DiaMedica Therapeutics during the second quarter valued at approximately $29,000. Bank of America Corp DE boosted its holdings in DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares during the last quarter. Finally, Farther Finance Advisors LLC bought a new stake in DiaMedica Therapeutics in the 4th quarter worth approximately $34,000. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.